Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImmunityBio, Inc.IBRX · Entity 3618 | Director | June 09, 2026 | June 11, 2026 |
| NantHealth, Inc.NH · Entity 109592 | Director | June 09, 2022 | June 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImmunityBio, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2036-06-09 | Direct | 65,600 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 65,600 · Balance 65,600 F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.
NantHealth, Inc.
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2032-06-09 | Direct | 100,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 100,000 · Balance 100,000 F1: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 00:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 65,600 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001371407-26-000003 · wk-form4_1781136707.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 65,600 shares Expires 2036-06-09 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 22:34 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 162,786 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001326110-25-000092 · wk-form4_1750458872.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,786 Underlying: Common Stock · 162,786 shares Expires 2035-06-18 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:49 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 77,633 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001326110-24-000077 · wk-form4_1718318948.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,633 Underlying: Common Stock · 77,633 shares Expires 2034-06-11 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 11, 2025 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:24 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 158,263 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001326110-23-000084 · wk-form4_1686867846.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,263 Underlying: Common Stock · 158,263 shares Expires 2033-06-13 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| June 05, 2023 Filed Jun 6, 2023 01:52 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | PurchaseCommon Stock | 485 | $2.75 | $1,333.75 |
DisclosureSEC source: 0001326110-23-000072 · wk-form4_1686016361.xml · nonDerivative · entry 3 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 71,915 Read SEC document |
| June 05, 2023 Filed Jun 6, 2023 01:52 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | PurchaseCommon Stock | 48,000 | $2.77 | $132,960.00 |
DisclosureSEC source: 0001326110-23-000072 · wk-form4_1686016361.xml · nonDerivative · entry 2 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 71,430 Read SEC document |
| June 05, 2023 Filed Jun 6, 2023 01:52 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | PurchaseCommon Stock | 23,430 | $2.72 | $63,729.60 |
DisclosureSEC source: 0001326110-23-000072 · wk-form4_1686016361.xml · nonDerivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 23,430 Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 01:16 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 167,937 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001326110-22-000047 · wf-form4_165534220571595.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,937 Underlying: Common Stock · 167,937 shares Expires 2032-06-14 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2023 or the date immediately preceding the 2023 annual meeting of stockholders. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:29 UTC | NantHealth, Inc. NH · Entity 109592 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0000899243-22-021909 · doc4.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. Read SEC document |
| June 16, 2021 Filed Jul 26, 2021 22:04 UTC | NantHealth, Inc. NH · Entity 109592 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0000899243-21-029926 · doc4.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:31 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 26,064 | $0.00 Strike: $14.91 | $0.00 |
DisclosureSEC source: 0001209191-21-040343 · doc4.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,064 Underlying: Common Stock · 26,064 shares Expires 2031-06-10 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 10, 2022 or the date immediately preceding the 2022 annual meeting of stockholders. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 22:19 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001209191-20-036030 · doc4.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 10, 2021 or the date immediately preceding the 2021 annual meeting of stockholders. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:16 UTC | NantHealth, Inc. NH · Entity 109592 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0000899243-20-014199 · doc4.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 23:37 UTC | NantHealth, Inc. NH · Entity 109592 | GrantStock Option (right to buy) · Derivative | 301,908 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000899243-19-017243 · doc4.xml · derivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,908 Underlying: Common Stock · 301,908 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the one year anniversary of the option grant date, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, subject to the Reporting Person's continuing to be a Service Provider (as defined in the 2016 Equity Incentive Plan) through the vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 20:35 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantCommon Stock | 92,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035558 · doc4.xml · nonDerivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,667 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · shares: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of June 6, 2020 or the date immediately preceding the 2020 annual meeting of stockholders. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 20:50 UTC | NantHealth, Inc. NH · Entity 109592 | GrantCommon Stock | 52,910 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024013 · doc4.xml · nonDerivative · entry 2 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,780 F1 · security: Each restricted stock unit ("RSU") is the economic equivalent of one share of NantHealth, Inc. common stock. F3 · shares: The RSUs shall vest on the earlier of (i) the one year anniversary of the date the RSU award is granted, or (ii) the day prior to the date of the Company's next annual meeting of the Company's stockholders, in each case, subject to the Reporting Person's continuing to be a service provider (as defined in the 2016 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 20:50 UTC | NantHealth, Inc. NH · Entity 109592 | GrantCommon Stock | 45,002 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-024013 · doc4.xml · nonDerivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,870 F1 · security: Each restricted stock unit ("RSU") is the economic equivalent of one share of NantHealth, Inc. common stock. F2 · shares: Subject to the Reporting Person's continuing to be a service provider (as defined in the 2016 Equity Incentive Plan) through each applicable vesting date, 33,751 RSUs shall be vested as of September 6, 2018, and the remaining 11,251 RSUs shall vest in installments as follows: 3,750 RSUs shall vest on each of December 7, 2018 and March 7, 2019, and 3,751 RSUs shall vest on June 7, 2019. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:15 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantCommon Stock | 27,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036919 · doc4.xml · nonDerivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,075 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · shares: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of June 7, 2019 or the date immediately preceding the 2019 annual meeting of stockholders. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 22:18 UTC | NantHealth, Inc. NH · Entity 109592 | GrantCommon Stock | 50,868 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-025617 · doc4.xml · nonDerivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,868 F1 · security: Each restricted stock unit ("RSU") is the economic equivalent of one share of NantHealth, Inc. common stock. F2 · shares: Subject to the Reporting Person's continuing to be a service provider (as defined in the 2016 Equity Incentive Plan) through each applicable vesting date, 21,195 RSUs shall be vested as of November 6, 2017, and the remaining 29,673 RSUs shall vest in equal installments on each three-month anniversary of the Vesting Commencement Date over a period of twenty-one (21) months after the Vesting Commencement Date (i.e., 4,239 RSUs shall vest on each of December 7, 2017, March 7, 2018, June 7, 2018, September 7, 2018, December 7, 2018, March 7, 2019 and June 7, 2019). Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 20:09 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantCommon Stock | 23,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039429 · doc4.xml · nonDerivative · entry 1 BLASZYK MICHAEL D · CIK 0001371407 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,753 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. F2 · shares: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the one year anniversary of the vesting commencement date on the same day of the month as the vesting commencement date. The vesting commencement date for this award is June 9, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.